The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | alloHCT plus fludarabine and treosulfan for secondary AML
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses a retrospective real-world study exploring whether allogeneic hematopoietic cell transplantation (alloHCT) with a myeloablative conditioning regimen of reduced toxicity, fludarabine and treosulfan (FluTreo), has a long-term survival advantage over previous transplant modalities for secondary acute myeloid leukemia (AML). The results showed the overall survival, relapse rates and graft-versus-host disease were all comparable with FluTreo to other transplants, allowing extension of the allo-HCT eligible population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
